Clinlogix, a full suite provider of clinical development services for medical device and biopharmaceutical customers, announces the launch of their new Asia-Pacific operations with staffed office openings in Singapore and Tokyo. The expansion into the Asia-Pacific market allows the company to extend and provide its tailored clinical development services through feet-on-the-ground staff with deep, country-specific expertise in both regulatory processes and partnering with clinical study sites to achieve its life science clients’ goals.
Clinlogix Asia Pacific is led by Managing Director Joalin Lim, PhD, who has more than 20 years of clinical and regulatory experience in Japan, China, Australia, Korea and rest of the Asia-Pacific market. Lim’s experience in clinical operations, regulatory affairs, health economics and reimbursement for prior companies such as Quintiles, Covidien and Abbott, among others, position her well for this role with Clinlogix. The team has significant experience in the region managing multi-center cardiovascular medical device clinical studies.
“The launch of the Asia-Pacific division allows Clinlogix to expand and deliver the customized, hands-on, quality clinical research services our global customers have come to expect from our other operations around the globe in the U.S., Europe and South America,” said JeanMarie Markham, Clinlogix CEO. “This will enable us to provide proper training, oversight and further develop our partnerships with clinical sites in these markets, which is vital to ensuring both the regulatory and clinical development success of our clients’ emerging medical technologies.”